|
|
Article: Genentech's Avastin Phase III Misses Breast Cancer Endpoint.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Anxiously awaited news regarding Avastin data from a Phase III study in breast cancer broke Tuesday, and - although many analysts had predicted mixed results at best - investors' faith in Genentech Inc.'s drug may have developed a few cracks.
"This was worse than expected," said Martin Auster, analyst with SunTrust Robinson Humphrey in Atlanta, calling South San Francisco-based Genentech "the most prolific and productive biotech industry member" despite a year of product setbacks.
Avastin (bevacizumab), an antibody directed at vascular endothelial growth factor (VEGF) missed its primary efficacy endpoint of progression-free ...